title: Brentuximab vedotin and bendamustine produce high complete response rates in patients with chemotherapy refractory Hodgkin lymphoma.
authors.affiliation: Center for Lymphoid Malignancies, Columbia University Medical Center, New York, NY, USA.|Department of Hematology and Oncology, Columbia University Medical Center, New York, NY, USA.
authors.forename: Matko
authors.initials: M
authors.lastname: Kalac
authors.affiliation: Center for Lymphoid Malignancies, Columbia University Medical Center, New York, NY, USA.|Department of Hematology and Oncology, Columbia University Medical Center, New York, NY, USA.
authors.forename: Jennifer K
authors.initials: JK
authors.lastname: Lue
authors.affiliation: Center for Lymphoid Malignancies, Columbia University Medical Center, New York, NY, USA.
authors.forename: Emily
authors.initials: E
authors.lastname: Lichtenstein
authors.affiliation: Center for Lymphoid Malignancies, Columbia University Medical Center, New York, NY, USA.
authors.forename: Ithamar
authors.initials: I
authors.lastname: Turenne
authors.affiliation: Center for Lymphoid Malignancies, Columbia University Medical Center, New York, NY, USA.
authors.forename: Celeste
authors.initials: C
authors.lastname: Rojas
authors.affiliation: Center for Lymphoid Malignancies, Columbia University Medical Center, New York, NY, USA.
authors.forename: Jennifer E
authors.initials: JE
authors.lastname: Amengual
authors.affiliation: Center for Lymphoid Malignancies, Columbia University Medical Center, New York, NY, USA.
authors.forename: Ahmed
authors.initials: A
authors.lastname: Sawas
authors.affiliation: Center for Lymphoid Malignancies, Columbia University Medical Center, New York, NY, USA.
authors.forename: Changchun
authors.initials: C
authors.lastname: Deng
authors.affiliation: Blood an Marrow Transplantation Program, Columbia University Medical Center, New York, NY, USA.
authors.forename: Markus Y
authors.initials: MY
authors.lastname: Mapara
authors.affiliation: Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, BC, USA.
authors.forename: Joseph M
authors.initials: JM
authors.lastname: Connors
authors.affiliation: Division of Medical Oncology and Hematology, University of Toronto, Princess Margaret Cancer Centre, Toronto, ON, USA.
authors.forename: John
authors.initials: J
authors.lastname: Kuruvilla
authors.affiliation: Center for Lymphoid Malignancies, Columbia University Medical Center, New York, NY, USA.
authors.forename: Owen A
authors.initials: OA
authors.lastname: O'Connor
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000069461:Bendamustine Hydrochloride / Q000008:administration & dosage; D000079963:Brentuximab Vedotin; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D018796:Immunoconjugates / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D018796:Immunoconjugates; D000079963:Brentuximab Vedotin; D000069461:Bendamustine Hydrochloride
keywords: Hodgkin lymphoma; antibody-drug conjugate; autologous stem cell transplant; monoclonal antibodies; refractory disease